GPCR profiling: From hits to leads and from genotype to phenotype

Drug Discovery Today: Technologies

Volumn 18, Issue , 2015, Pages 30-37

  Cvijic, Mary Ellen ^a   Sum, Chi Shing ^a   Alt, Andrew ^a   Zhang, Litao ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; MOLECULAR LIBRARY; PROTEIN BINDING;

ALLOSTERISM; BINDING SITE; CELLULAR DISTRIBUTION; CRYSTALLIZATION; DRUG MECHANISM; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; LABORATORY AUTOMATION; LIGAND BINDING; MUTAGENESIS; PHENOTYPE; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES;

ANIMALS; BINDING SITES; DRUG DISCOVERY; GENOTYPE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84955291119     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2015.10.005     Document Type: Review

References (35)

1. R.M. Eglen, R. Bosse, and G.S. Long Deja vu all over again: emerging concepts of G protein-coupled receptor (GPCR) function and drug discovery Drug Discov World 6 2006 69 77
2. M. Rask-Andersen, M.S. Almen, and H.B. Schioth Trends in the exploitation of novel drug targets Nat Rev Drug Discov 10 2011 579 590
3. G-Protein Coupled Receptor (GPCR) targeting: technologies and global markets BCC Res 2014
4. J. Bowes, A.J. Brown, J. Hamon, W. Jarolimek, A. Sridhar, G. Waldron, and et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Nat Rev Drug Discov 11 2012 909 922
5. B.L. Roth Drugs and valvular heart disease N Engl J Med 356 2007 6 9
6. A. Olasinska-Wisniewska, J. Olasinski, and S. Grajek Cardiovascular safety of antihistamines Postepy Dermatol Alergol 31 2014 182 186
7. R.J. Rodgers, M.H. Tschop, and J.P. Wilding Anti-obesity drugs: past, present and future Dis Model Mech 5 2012 621 626
8. R.M. Eglen, and T. Reisine GPCRs revisited: new insights lead to novel drugs Pharmaceuticals 4 2011 244 272
9. P.J. Conn, C.W. Lindsley, J. Meiler, and C.M. Niswender Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders Nat Rev Drug Discov 13 2014 692 708
10. L. Zhang, M.E. Cvijic, J. Lippy, J. Myslik, S.L. Brenner, A. Binnie, and et al. Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009 Drug Discov Today 17 2012 733 740
11. E. Jacoby, R. Bouhelal, M. Gerspacher, and K. Seuwen The 7 TM G-protein-coupled receptor target family ChemMedChem 1 2006 761 782
12. A.L. Rodriguez, M.D. Grier, C.K. Jones, E.J. Herman, A.S. Kane, R.L. Smith, and et al. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol Pharmacol 78 2010 1105 1123
13. E. Smith, P. Chase, C.M. Niswender, T.J. Utley, D.J. Sheffler, M.J. Noetzel, and et al. Application of parallel multiparametric cell-based flipr detection assays for the identification of modulators of the muscarinic acetylcholine receptor 4 (M4) J Biomol Screen 20 2015 858 868
14. E. Kostenis, M. Waelbroeck, and G. Milligan Techniques: promiscuous Gα proteins in basic research and drug discovery Trends Pharmacol Sci 26 2005 595 602
15. D.J. Noblin, R.L. Bertekap Jr., N.T. Burford, A. Hendricson, L. Zhang, R. Knox, and et al. Development of a high-throughput calcium flux assay for identification of all ligand types including positive, negative, and silent allosteric modulators for G protein-coupled receptors Assay Drug Dev Technol 10 2012 457 467
16. R.L.J. Bertekap, N.T. Burford, Z. Li, and A. Alt High-throughput screening for allosteric modulators of GPCRs M. Filizola, G protein-coupled receptors in drug discovery 2nd Ed. 2015 Springer 223 240
17. R. Zhang, and X. Xie Tools for GPCR drug discovery Acta Pharmacol Sin 33 2012 372 384
18. G. Zhang, and M.E. Cvijic Screening and characterization of G-protein-coupled receptor ligand for drug discovery R. Seethala, L. Zhang, Handbook of drug screening 2009 Informa Healthcare USA, Inc.
19. M.E. Cvijic, J. Chen, S. Kubala, J. Nolfo, G. Kolodin, and L. Zhang GPCR assay automation for leveraging lead optimization J Lab Autom 17 2012 266 274
20. J.A. Allen, and B.L. Roth Strategies to discover unexpected targets for drugs active at G protein-coupled receptors Annu Rev Pharmacol Toxicol 51 2011 117 144
21. K.P. Cusack, Y. Wang, M.Z. Hoemann, J. Marjanovic, R.G. Heym, and A. Vasudevan Design strategies to address kinetics of drug binding and residence time Bioorg Med Chem Lett 25 2015 2019 2027
22. M.A. Lewis, L. Hunihan, J. Watson, R.G. Gentles, S. Hu, Y. Huang, and et al. Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity J Pharmacol Exp Ther 354 2015 340 349
23. M. Azzi, P.G. Charest, S. Angers, G. Rousseau, T. Kohout, M. Bouvier, and et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors Proc Natl Acad Sci U S A 100 2003 11406 11411
24. S.M. DeWire, and J.D. Violin Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology Circ Res 109 2011 205 216
25. J.D. Violin, A.L. Crombie, D.G. Soergel, and M.W. Lark Biased ligands at G-protein-coupled receptors: promise and progress Trends Pharmacol Sci 35 2014 308 316
26. M.T. Griffin, K.W. Figueroa, S. Liller, and F.J. Ehlert Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15 J Pharmacol Exp Ther 321 2007 1193 1207
27. T. Kenakin, C. Watson, V. Muniz-Medina, A. Christopoulos, and S. Novick A simple method for quantifying functional selectivity and agonist bias ACS Chem Neurosci 3 2012 193 203
28. K.J. Gregory, N.E. Hall, A.B. Tobin, P.M. Sexton, and A. Christopoulos Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias J Biol Chem 285 2010 7459 7474
29. E.T. van der Westhuizen, B. Breton, A. Christopoulos, and M. Bouvier Quantification of ligand bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy Mol Pharmacol 85 2014 492 509
30. Y. Zhu, J. Watson, M. Chen, D.R. Shen, M. Yarde, M. Agler, and et al. Integrating high-content analysis into a multiplexed screening approach to identify and characterize GPCR agonists J Biomol Screen 19 2014 1079 1089
31. C.W. Scott, and M.F. Peters Label-free whole-cell assays: expanding the scope of GPCR screening Drug Discov Today 15 2010 704 716
32. Y. Fang Label-free drug discovery Front Pharmacol 5 2014 52
33. I. Navratilova, J. Besnard, and A.L. Hopkins Screening for GPCR ligands using surface plasmon resonance ACS Med Chem Lett 2 2011 549 554
34. N.T. Burford, J. Watson, R. Bertekap, and A. Alt Strategies for the identification of allosteric modulators of G-protein-coupled receptors Biochem Pharmacol 81 2011 691 702
35. S. Sharma, A.L. Rodriguez, P.J. Conn, and C.W. Lindsley Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold Bioorg Med Chem Lett 18 2008 4098 4101